Hosta

by | Mar 16, 2018 | Hosta

How Can We Help?
You are here:
< Back

LY-367,265 is a drug developed by Eli Lilly, which acts as both a potent and selective antagonist at the serotonin 5-HT2A receptor, and also a selective serotonin reuptake inhibitor (SSRI). It has antidepressant effects in animal studies, reduces glutamate signalling in the brain and increases the analgesic effects of morphine.[1][2][3]

References

  1. ^ Pullar IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S (October 2000). "LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone". European Journal of Pharmacology. 407 (1–2): 39–46. doi:10.1016/S0014-2999(00)00728-7. PMID 11050288.
  2. ^ Wang SJ (March 2005). "Potential antidepressant LY 367265 presynaptically inhibits the release of glutamate in rat cerebral cortex". Synapse. 55 (3): 156–63. doi:10.1002/syn.20104. PMID 15602751. S2CID 11860623.
  3. ^ Ozdemir E, Bagcivan I, Gursoy S, Altun A, Durmus N (June 2011). "Effects of fluoxetine and LY 367265 on tolerance to the analgesic effect of morphine in rats". Acta Physiologica Hungarica. 98 (2): 205–13. doi:10.1556/APhysiol.98.2011.2.12. PMID 21616779.
Categories
Table of Contents